Clinicians are calling for greater investment in bariatric surgery after a new report shows that such surgery has significant and varied health benefits for patients in the United Kingdom.
The report claims to show for the first time on a nationwide scale the positive effects of bariatric surgery in treating a range of life threatening diseases, including an 85% reduction in the number of patients with type 2 diabetes two years after surgery.
The first report by the UK national bariatric surgery registry-a consortium of the Association of Laparoscopic Surgeons, the Association of Upper Gastrointestinal Surgeons, and the British Obesity and Metabolic Surgical Society-was published on 13 April jointly with the company Dendrite Clinical Systems. Almost 10 000 bariatric surgeries were carried out in 2010 in the UK, but varied commissioning meant that around half were done in the private sector.
Data from 86 hospitals showed that, by the time they reached surgery, around two thirds of severely obese patients had three or more associated diseases. Around a third (32%) had hypertension, over a quarter (27%) had type 2 diabetes, 17% had a high cholesterol concentration, and 15% had sleep apnoea.
Twelve months after surgery 20% had hypertension, 13% had diabetes, 8% had high cholesterol, and 6% had sleep apnoea.
At two years of follow-up 86% of those affected by diabetes before surgery showed no indication of the disease, the data showed.
The figures, which recorded the success rates for four bariatric procedures, including gastric bypass and gastric band, also showed that the in-hospital death rate among patients undergoing surgery to treat obesity was 0.1%. By comparison, 2008 figures for the UK show that the death rate among patients having coronary artery bypass graft surgery was 2.4% and that for abdominal aortic aneurysm repair was just over 4%.
The three organisations behind the work said that the results provided evidence that obesity surgery was one of the most clinically effective, safe, and cost effective treatments available to the NHS.
They called on the Department of Health to invest in a long term strategy to ensure that all patients had equal access to treatment delivered by experienced teams working out of properly equipped centres.
The cost of bariatric surgery was recouped within three years of surgery, they said, because obesity associated costs were eliminated, with diabetes alone estimated to cost the health service £3000 (€3400; $4900) a year for life for each patient, while the direct costs of treating obesity related illness overall was £5bn a year.
Alberic Fiennes, a bariatric surgeon and chairman of the registry's data committee, said: "These data show that not only is UK bariatric surgery safe but it successfully treats a whole range of diseases, including the rapid resolution of diabetes, yet commissioners continue to ignore the facts.
"An approach that limits treatment to a fraction of those who would benefit is one which the NHS will rue in years to come as these patients become an unsustainable burden on the health service." John Black, president of the Royal College of Surgeons, said, "It is a false economy to cut funding for this type of surgery. Any short term savings are tiny compared with the real ongoing cost of treating obese patients. We call upon the Department of Health to promote bariatric surgery."
